In a 9-6 vote, an advisory panel said the FDA should not yet approve dapagliflozin, a new type of diabetes drug that makes the body dump sugar and lose weight. Signals of possible cancer and liver damage worried the experts.
Continue reading here:
FDA Panel Opposes New Type of Diabetes Drug